Events2Join

Masitinib is a broad coronavirus 3CL inhibitor that blocks replication ...


Validation and invalidation of SARS-CoV-2 main protease inhibitors ...

Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2. Science. 2021; 373: 931-6. 11. Xia Z, Sacco M, Hu Y ...

Gain-of-Signal Assays for Probing Inhibition of SARS-CoV-2 Mpro ...

Last, masitinib was identified recently as a pan-coronavirus inhibitor ... broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2.

CoV 3C-like (main) protease | Coronavirus (CoV) proteins

The crystal structure of SARS-CoV-2 Main Protease in complex with masitinib ... (2021) Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of ...

Repurposing clinically available drugs and therapies for pathogenic ...

Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2. Science. 2021; 373(6557): 931–936. 10.1126/science ...

Structural Basis for the Inhibition of Coronaviral Main Proteases by a ...

Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2 · N. DraymanJ. Demarco +35 authors. S. Tay. Medicine. Science. 2021. TLDR.

Computationally prioritized drugs inhibit SARS-CoV-2 infection and ...

, et al. Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2 . Science. 2021. ;. 373. : 931. –. 36 . Google ...

Discovery of potential anti-SARS-CoV-2 drugs based on large-scale ...

Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2. Science 373, 931–936. Article CAS PubMed PubMed ...

Masitinib - Wikipedia

Masitinib is a tyrosine kinase inhibitor which inhibits ... "Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2".

Coronavirus Antivirals - Tocris Bioscience

... CoV-2 interactome; potent calcineurin inhibitor. 7229, Galidesivir dihydrochloride. Broad spectrum antiviral nucleotide; inhibits coronavirus replication in ...

AB Science announces the signing of an exclusive licensing

Drug repurposing screen identifies masitinib as a 3CLpro inhibitor that blocks replication of SARS-CoV-2 in vitro. bioRxiv 2020.08.31.274639 ...

The role of chemical biology in the fight against SARS-CoV-2

N.I.. et al. (. 2020. ) Drug repurposing screen identifies masitinib as a 3CLpro inhibitor that blocks replication of SARS-CoV-2 in vitro.

Existing Drug Is Shown to Inhibit Virus That Causes COVID-19

... coronaviruses that allows them to replicate inside a cell. They found that of the drug candidates, masitinib completely inhibited the 3CL viral enzyme ...